- Posted June 28, 2013
- Tweet This | Share on Facebook
Esperion Therapeutics shares jump in trading debut
NEW YORK (AP) -- Shares of Esperion Therapeutics Inc. jumped Wednesday in their first day of trading after the drug developer raised $70 million in an initial public offering.
In midday trading, the drug developer's shares rose $1.27, or 9 percent, to $15.27, after jumping as high as $17.40 earlier in the session. Earlier, Esperion sold 5 million shares for $14 each, resulting in $70 million in proceeds.
Esperion is developing a new kind of experimental drug that would lower LDL cholesterol, commonly known as "bad" cholesterol. Roger Newton, the company's founder, executive chairman and chief scientific officer, is a co-discoverer of the cholesterol drug Lipitor, the world's top-selling drug for more than a decade.
The shares are trading on the Nasdaq under the ticker symbol "ESPR." The company is based in Plymouth, Mich.
Published: Fri, Jun 28, 2013
headlines Oakland County
headlines National
- New Legalese: You may have heard a deepfake, but what about ‘Twiqbal’?
- From Intake to Outcome: An in-house lawyer’s guide to matter management solutions
- 2 BigLaw firms in merger talks that could produce 1,600-lawyer firm with top 50 revenue
- Send in the paralegals
- Lawyer reprimanded after mistakenly emailing opposing counsel with plan to avoid judge’s call
- ‘I don’t play well’ judge who threatened to track down, jail misbehaving litigant gets tossed from case